Table 3.
Antimicrobial activities of telavancin and comparator antimicrobial agents tested against a worldwide collection of Gram-positive clinical isolates (2010)
| Organism (no. tested) and antimicrobial agentf | MIC (μg/ml) |
% susceptible/resistanta |
|||
|---|---|---|---|---|---|
| Range | 50% | 90% | CLSI | EUCAST | |
| MSSA (4,565) | |||||
| Telavancinb | 0.03–0.5 | 0.12 | 0.25 | 100.0/−c | 100.0/− |
| Vancomycin | 0.25–2 | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤1–4 | ≤1 | ≤1 | 100.0/0.0 | >99.9/<0.1 |
| Daptomycin | ≤0.06–1 | 0.25 | 0.5 | 100.0/− | 100.0/0.0 |
| Linezolid | ≤0.12–2 | 1 | 2 | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | ≤0.5–>4 | ≤0.5 | ≤0.5 | 91.7/7.6 | 91.7/7.6 |
| Erythromycin | ≤0.25–>4 | ≤0.25 | >4 | 76.4/21.7 | 76.4/22.7 |
| Clindamycin | ≤0.25–>2 | ≤0.25 | ≤0.25 | 95.1/4.6 | 94.5/4.9 |
| Quinupristin-dalfopristin | ≤0.5–4 | ≤0.5 | ≤0.5 | 99.9/0.1 | 99.9/0.1 |
| Gentamicin | ≤1–>8 | ≤1 | ≤1 | 97.5/2.1 | 96.6/3.4 |
| Tetracycline | ≤0.25–>8 | ≤0.25 | 0.5 | 94.3/5.0 | 93.6/6.1 |
| Trimethoprim-sulfamethoxazole | ≤0.5–>4 | ≤0.5 | ≤0.5 | 99.1/0.9 | 99.1/0.7 |
| MRSA (3,088) | |||||
| Telavancin | ≤0.015–0.5 | 0.12 | 0.25 | 100.0/− | |
| Vancomycin | 0.25–2 | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤1–4 | ≤1 | ≤1 | 100.0/0.0 | 99.5/0.5 |
| Daptomycin | ≤0.06–2 | 0.25 | 0.5 | 99.9/− | 99.9/0.1 |
| Linezolid | ≤0.12–8 | 1 | 1 | >99.9/<0.1 | >99.9/<0.1 |
| Levofloxacin | ≤0.5–>4 | >4 | >4 | 24.1/74.1 | 24.1/74.1 |
| Erythromycin | ≤0.25–>4 | >4 | >4 | 16.4/82.9 | 16.4/83.2 |
| Clindamycin | ≤0.25–>2 | ≤0.25 | >2 | 59.2/40.7 | 58.9/40.8 |
| Quinupristin-dalfopristin | ≤0.5–>4 | ≤0.5 | ≤0.5 | 99.7/0.1 | 99.7/0.1 |
| Gentamicin | ≤1–>8 | ≤1 | >8 | 83.0/16.5 | 82.3/17.7 |
| Tetracycline | ≤0.25–>8 | ≤0.25 | >8 | 87.6/12.1 | 84.3/12.7 |
| Trimethoprim-sulfamethoxazole | ≤0.5–>4 | ≤0.5 | ≤0.5 | 95.0/5.0 | 95.0/4.7 |
| CoNS (1,278) | |||||
| Telavancin | ≤0.015–1 | 0.12 | 0.25 | −/− | −/− |
| Vancomycin | 0.25–4 | 1 | 2 | 100.0/0.0 | 99.3/0.7 |
| Teicoplanin | ≤1–>8 | 2 | 4 | 99.1/0.0 | 90.8/9.2 |
| Daptomycin | ≤0.06–2 | 0.25 | 0.5 | 99.8/− | 99.8/0.2 |
| Linezolid | ≤0.12–>8 | 0.5 | 1 | 99.4/0.6 | 99.4/0.6 |
| Oxacillin | ≤0.25–>2 | >2 | >2 | 26.0/74.0 | 26.0/74.0 |
| Levofloxacin | ≤0.5–>4 | 2 | >4 | 46.2/48.8 | 46.2/48.8 |
| Erythromycin | ≤0.25–>4 | >4 | >4 | 36.1/62.6 | 36.1/63.2 |
| Clindamycin | ≤0.25–>2 | ≤0.25 | >2 | 65.5/33.0 | 64.2/34.5 |
| Quinupristin-dalfopristin | ≤0.5–>4 | ≤0.5 | ≤0.5 | 99.1/0.4 | 99.1/0.4 |
| Gentamicin | ≤1–>8 | ≤1 | >8 | 67.5/23.0 | 57.8/42.2 |
| Tetracycline | ≤0.25–>8 | 1 | >8 | 85.2/13.4 | 72.0/16.1 |
| Trimethoprim-sulfamethoxazole | ≤0.5–>4 | ≤0.5 | >4 | 63.7/36.3 | 63.7/20.8 |
| E. faecalis (1,459) | |||||
| Vancomycin-susceptible (1,421) | |||||
| Telavancin | 0.03–1 | 0.5 | 0.5 | 100.0/− | |
| Ampicillin | ≤1–8 | ≤1 | 2 | 100.0/0.0 | 99.6/0.0 |
| Vancomycin | 0.25–4 | 1 | 2 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤1–2 | ≤1 | ≤1 | 100.0/0.0 | 100.0/0.0 |
| Daptomycin | ≤0.06–4 | 1 | 1 | 100.0/− | −/− |
| Linezolid | 0.25–>8 | 1 | 2 | 99.9/0.1 | 99.9/0.1 |
| Levofloxacin | ≤0.5–>4 | 1 | >4 | 69.2/30.2 | −/− |
| VanA-type E. faecalis (32) | |||||
| Telavancin | 2–>2 | >2 | >2 | −/− | −/− |
| Ampicillin | ≤1–2 | ≤1 | 2 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | >8 | >8 | >8 | 0.0/100.0 | 0.0/100.0 |
| Daptomycin | 0.5–2 | 1 | 1 | 100.0/− | −/− |
| Linezolid | 0.5–2 | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | 1–>4 | >4 | >4 | 6.3/93.8 | −/− |
| VanB-type E. faecalis (6) | |||||
| Telavancin | 0.25–1 | 0.5 | − | −/− | −/− |
| Ampicillin | ≤1–2 | ≤1 | − | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤1–2 | ≤1 | − | 100.0/0.0 | 100.0/0.0 |
| Daptomycin | 0.5–2 | 0.5 | − | 100.0/− | −/− |
| Linezolid | 0.5–1 | 1 | − | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | >4 | >4 | − | 0.0/100.0 | −/− |
| E. faecium | |||||
| Vancomycin-susceptible (386) | |||||
| Telavancin | ≤0.015–0.25 | 0.06 | 0.12 | −/− | −/− |
| Ampicillin | ≤1–>8 | >8 | >8 | 14.2/85.8 | 13.7/85.8 |
| Vancomycin | 0.25–4 | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤1–4 | ≤1 | ≤1 | 100.0/0.0 | 99.7/0.3 |
| Daptomycin | ≤0.06–4 | 2 | 2 | 100.0/− | −/− |
| Linezolid | 0.5–8 | 1 | 2 | 99.2/0.8 | 99.2/0.8 |
| Levofloxacin | ≤0.5–>4 | >4 | >4 | 12.7/82.9 | −/− |
| Quinupristin-dalfopristin | ≤0.5–>4 | ≤0.5 | 4 | 71.8/11.9 | 71.8/1.0 |
| VanA-type E. faecium (392) | |||||
| Telavancin | 0.25–>2 | 2 | >2 | −/− | −/− |
| Ampicillin | ≤1–>8 | >8 | >8 | 0.3/99.7 | 0.3/99.7 |
| Teicoplanin | >8 | >8 | >8 | 0.0/100.0 | 0.0/100.0 |
| Daptomycin | 0.12–8 | 2 | 2 | 99.5/− | −/− |
| Linezolid | 0.5–>8 | 1 | 1 | 98.7/0.3 | 99.7/0.3 |
| Levofloxacin | >4 | >4 | >4 | 0.0/100.0 | −/− |
| Quinupristin-dalfopristin | ≤0.5–>4 | ≤0.5 | 1 | 97.2/1.0 | 97.2/1.0 |
| VanB-type E. faecium (27) | |||||
| Telavancin | ≤0.015–1 | 0.12 | 0.5 | −/− | −/− |
| Ampicillin | >8 | >8 | >8 | 0.0/100.0 | 0.0/100.0 |
| Teicoplanin | ≤1–8 | ≤1 | 8 | 100.0/0.0 | 77.8/22.2 |
| Daptomycin | 0.12–2 | 2 | 2 | 100.0/− | −/− |
| Linezolid | 0.5–4 | 1 | 2 | 96.3/0.0 | 100.0/0.0 |
| Levofloxacin | 4–>4 | >4 | >4 | 0.0/100.0 | −/− |
| Quinupristin-dalfopristin | ≤0.5–4 | ≤0.5 | 1 | 88.9/7.4 | 88.9/0.0 |
| S. pneumoniae (2,150) | |||||
| Telavancin | ≤0.015–0.12 | ≤0.015 | 0.03 | −/− | −/− |
| Vancomycin | ≤0.12–1 | 0.25 | 0.5 | 100.0/− | 100.0/0.0 |
| Teicoplanin | ≤1 | ≤1 | ≤1 | −/− | 100.0/0.0 |
| Linezolid | ≤0.12–4 | 1 | 1 | >99.9/− | 100.0/0.0 |
| Penicillin | ≤0.03–>4 | ≤0.03 | 4 | 87.6/0.6d/61.9/22.4e | 61.9/12.4 |
| Levofloxacin | ≤0.5–>4 | 1 | 1 | 98.8/1.1 | 98.8/1.2 |
| Erythromycin | ≤0.25–>4 | ≤0.25 | >4 | 59.2/40.0 | 59.2/40.0 |
| Clindamycin | ≤0.25–>1 | ≤0.25 | >1 | 72.3/27.3 | 72.7/27.3 |
| Tetracycline | ≤0.25–>8 | 0.5 | >8 | 67.7/32.0 | 67.3/32.3 |
| Beta-hemolytic streptococci (1,472) | |||||
| Telavancin | ≤0.015–0.25 | 0.06 | 0.12 | 99.8/− | |
| Penicillin | ≤0.03–0.12 | ≤0.03 | 0.06 | 100.0/− | 100.0/0.0 |
| Vancomycin | ≤0.12–1 | 0.5 | 0.5 | 100.0/− | 100.0/0.0 |
| Teicoplanin | ≤1 | ≤1 | ≤1 | −/− | 100.0/0.0 |
| Daptomycin | ≤0.06–0.5 | ≤0.06 | 0.25 | 100.0/− | 100.0/0.0 |
| Linezolid | ≤0.12–2 | 1 | 1 | 100.0/− | 100.0/0.0 |
| Levofloxacin | ≤0.5–>4 | ≤0.5 | 1 | 98.4/1.3 | 94.7/1.6 |
| Erythromycin | ≤0.25–>4 | ≤0.25 | >4 | 75.3/23.6 | 75.3/23.6 |
| Clindamycin | ≤0.25–>2 | ≤0.25 | >2 | 87.5/12.0 | 88.0/12.0 |
| Viridans group streptococci (519) | |||||
| All (519) | |||||
| Telavancin | ≤0.015–0.12 | 0.03 | 0.06 | 100.0/− | 100.0/− |
| Penicillin | ≤0.03–>4 | 0.06 | 1 | 74.0/5.4 | 84.0/5.4 |
| Vancomycin | ≤0.12–1 | 0.5 | 0.5 | 100.0/− | 100.0/0.0 |
| Teicoplanin | ≤1 | ≤1 | ≤1 | −/− | 100.0/0.0 |
| Daptomycin | ≤0.06–2 | 0.25 | 0.5 | 99.6/− | −/− |
| Linezolid | ≤0.12–2 | 1 | 1 | 100.0/− | −/− |
| Levofloxacin | ≤0.5–>4 | 1 | 2 | 92.5/6.2 | −/− |
| Erythromycin | ≤0.25–>4 | ≤0.25 | >4 | 52.2/45.1 | −/− |
| Clindamycin | ≤0.25–>2 | ≤0.25 | >2 | 86.9/12.1 | 87.9/12.1 |
| S. bovis group (32) | |||||
| Telavancin | ≤0.015–0.12 | 0.03 | 0.06 | 100.0/− | 100.0/− |
| Penicillin | ≤0.03–0.12 | ≤0.03 | 0.06 | 100.0/0.0 | 100.0/0.0 |
| Vancomycin | 0.25–0.5 | 0.25 | 0.5 | 100.0/− | 100.0/0.0 |
| Teicoplanin | ≤1 | ≤1 | ≤1 | −/− | 100.0/0.0 |
| Daptomycin | ≤0.06–0.12 | ≤0.06 | ≤0.06 | 100.0/− | −/− |
| Linezolid | 0.5–2 | 1 | 1 | 100.0/− | −/− |
| Levofloxacin | ≤0.5–2 | 1 | 2 | 100.0/0.0 | −/− |
| Erythromycin | ≤0.25–>4 | ≤0.25 | >4 | 59.4/37.5 | −/− |
| Clindamycin | ≤0.25–>2 | ≤0.25 | >2 | 75.0/25.0 | 75.0/25.0 |
a
Criteria for susceptibility as published by the Clinical and Laboratory Standards Institute (M100-S21, 2011) and the European Committee on Antimicrobial Susceptibility Testing (2011).
b
For telavancin, the FDA-approved susceptible breakpoints for S. aureus (≤1 μg/ml), vancomycin-susceptible E. faecalis (≤1 μg/ml), viridans group streptococci (≤0.12 μg/ml), and beta-hemolytic streptococci (≤0.12 μg/ml) were applied.
c
−, no breakpoint available.
d
Penicillin, parenteral (nonmeningitis).
e
Penicillin (oral penicillin V).
f
Abbreviations: MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; CoNS, coagulase-negative staphylococci.